H.C. Wainwright Remains a Buy on Disc Medicine (IRON)
In a report released on June 8, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Disc Medicine. The company’s shares closed yesterday at $65.80.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Tsao covers the Healthcare sector, focusing on stocks such as Rezolute, Cabaletta Bio, and Praxis Precision Medicines. According to TipRanks, Tsao has an average return of 17.4% and a 50.80% success rate on recommended stocks.
Currently, the analyst consensus on Disc Medicine is a Strong Buy with an average price target of $100.67, representing a 52.99% upside. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $88.00 price target.
Based on Disc Medicine’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $63.5 million. In comparison, last year the company had a GAAP net loss of $34.09 million
Read More on IRON:
Disclaimer & DisclosureReport an Issue
- Disc Medicine Buy Rating Reiterated as APOLLO Phase III Progress and Bitopertin Outlook Support Unchanged $100 Price Target
- Disc Medicine: Outperform Rating Reiterated as Advancing Rare-Hematology Pipeline Supports Unchanged $100 Price Target
- Disc Medicine presents updated data from RALLY-MF trial at ASCO
- Disc Medicine price target raised to $80 from $75 at Morgan Stanley
- Disc Medicine reports Q1 EPS ($1.65), consensus ($1.73)
